Lipocine Inc reports results for the quarter ended in January - Earnings Summary

Lipocine

08/08/2024 14:31

* Lipocine Inc  LPCN.OQ  reported a quarterly adjusted loss
of 57
cents​​ per share for the quarter ended in January, higher than
the same quarter last year, when the company reported EPS of -68
cents.  The lone analyst forecast for the quarter was for a loss
of 78 cents per share. 
    * Revenue was $89.57 thousand​; analysts expected $290.00
thousand. 
    * Lipocine Inc's reported EPS for the quarter was a loss
of 57
cents​.
    * The company reported a quarterly loss of $3.07 million.
    * Lipocine Inc shares had fallen by 38.8% this quarter and
gained 80.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 25.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Lipocine Inc is
$33.00 
This summary was machine generated from LSEG data August 8 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.78          -0.57          Beat
 Mar. 31 2024      -0.68          0.66           Beat
 Dec. 31 2023      -0.47          -0.42          Beat
 Sep. 30 2023      -0.60          -1.27          Missed